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So wretched and miserable is the condition of man¬ 
kind that not only are men tormented by innumerable ills 
throughout their lives, but foetuses also are not free 
from evils and sicknesses whilst they are still shut up 
within the prison of the womb, and before they breathe 
with joy the vital air and look upon the light...(and) 
from this it becomes abundantly clear that there is great 
sympathy and affinity between the mother and the foetus. 
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I. INTRODUCTION 
Erythroblastosis fetalis has about a 5 percent chance of 
occurring in Rh negative mothers with Rh positive fathers, that 
is, once in every 150 to 200 births.1 Among these cases, mortality 
in the first affected pregnancy is 7-10 percent, serious illness 
requiring transfusions accounts for 60 percent, and mild illness 
30 percent.2 
Studies of the pathogenesis of this disease, since Levine's 
original report in 19^1,^ have centered on possible causes of iso¬ 
immunization in terms of sensitization following the entrance of 
fetal erythrocytes into the maternal circulation.^ This event has 
been shown to occur during all trimesters of pregnancy as well as 
postpartum.5one striking finding has been that maternal-fetal 
ABO incompatibility is associated with a decreased probability of 
the Rh disease occurring,^ and, according to some investigators, 
O 
decreased severity. These phenomena are explained by the hypothesis 
that when ABO incompatible fetal cells enter the maternal circulation 
they are likely to be destroyed by the appropriate anti-A or anti-B 
8 9 
antibodies, thereby diminishing the potential source of sensitization. ’ 
Factors promoting maternal uterine trauma at delivery, such as manual 
removal of the placenta and Cesarean section, have been suggested as 
promoting the transfer of fetal erythrocytes into the maternal circula¬ 
tion, but evidence linking such events to subsequent erythroblastosis 
fetalis is meager. Potter mentions an increased incidence of complica¬ 
tions of labor as associated with later hemolytic disease of the newborn. 
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but provides no data.10 In a series of 46 patients, Gainey et al. noted 
3 cases of traumatic deliveries, 4 of Cesarean section, and 3 of man¬ 
ual removal of the placenta compared to one Cesarean section in a 
control series of 38 patients, and suggest "induced pathology" may 
lead to maternal isoimmunization.11 
The prognosis of the disease once sensitization has occurred 
is that later pregnancies with Rh positive children tend to have the 
1 O 
disease to the same or greater extent than the first affected child. 
Factors relating to the prognosis of the first affected child have in¬ 
volved evaluation of the maternal anti-Rh antibody titer and the 
optical absorption spectrum of the amniotic fluid, both events which 
To 
occur after sensitization. Ttee this writer's knowledge no reports 
relating prognosis to the events of presumed sensitization have appear¬ 
ed beyond the recognition of the "protective" effects of maternal- 
fetal ABO incompatibility. 
This study, then, undertakes to evaluate the clinical events surround¬ 
ing sensitization in terms of the subsequent development and prognosis 
of erythroblastosis fetalis in the first affected child. For instance, 
the hypothesis that prolonged or difficult labor is associated with 
an increased likelihood of maternal sensitization may be tested, as 
may also the hypothesis that prolonged or difficult labor is of prog¬ 
nostic importance. Thus subjected to analysis are the obstetrical 
data involving the presumed sensitizing pregnancy and delivery and the 
equally readily available pediatric data involving the presence and 
severity of erythroblastosis fetalis. 
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II. MATERIALS AND METHODS 
A. Criteria of Patient Selection. 
Twenty-five cases of first affected children with erythro¬ 
blastosis fetalis were selected from the records of the Grace-New 
Haven Hospital for the period 1960-1962 according to the following 
criteria: 
1. ABO blood types of mother, erythroblastoticchild, 
and preceding sibling(s) are known, and the Rh types appropriate, 
i.e., mother Rh negative, erythroblastotic child Rh positive, a 
preceding sibling Rh positive, and the father (when known) Rh 
positive. 
2. The mother had before delivery of the erythroblas¬ 
totic child received no blood transfusions or injections. 
3. The erythroblastotic child had a positive Coombs test.1^ 
4. Patients were excluded which involved, 
a. non-white racial background, 
b. a multiple pregnancy, or 
c. Cesarean section for an Rh positive child prior to 
delivery of a sensitized one. 
5. Appropriate controls were available. 
Controls were selected so that each case of erythroblastosis 
fetalis had an individual control meeting the following criteria: 
1. No erythroblastosis fetalis was present (Coombs test 
negative in all children). 
2. Maternal and paternal (when known) ABO and Rh blood types 
were the same as those of the corresponding mother and father (when 
known). 
3. The ABO and Rh blood types of each living newborn were 
identical with those of the corresponding child, including the first 
affected. For example, if an 0 negative mother and an A positive 
father have a normal A positive first offspring, normal 0 negative 
second, and erythroblastotic A positive third, then these same blood 
types must be present in the control, i.e., 0 negative mother, A 
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positive father, A positive first offspring, 0 negative second, and 
A positive third. 
U. Patients were excluded which had, 
a. a non-white racial background, 
b. a plural pregnancy, or 
c. Cesarean section for an Rh positive child prior to 
delivery corresponding to the sensitized one. 
These latter two restrictions were deemed necessary because 
twinning and Cesarean sections occur too infrequently to permit of 
controlling. 
Using the above criteria, a series of twenty-five plus con¬ 
trols was obtained. 
B. Limitations and Values of Patient Selection. 
It will be noted that these criteria for case selection 
provide a sample of erythroblastosis fetalis which excludes the 
15 to 20 percent of cases which die 111 utero, for on these children 
ABO, Rh, and Coombs testing are not done. Also tending to be elim¬ 
inated from consideration are those cases involving unusual combin¬ 
ations of blood types, for controls with these same combinations 
are difficult to obtain. 
The selection is skewed away from the most grave occurr¬ 
ence of the disease, and away from unusual combinations of blood 
types. 
Also the series is rather small due to many incomplete records 
by the above criteria. However, because these limitations apply equally 
. 
5- 
to the control series, so comparison provides internally valid 
results. 
C. Material Under Study 
Three categories of data are considered: Personal maternal 
data, such as height and weight; data relating to the presumed sensi¬ 
tizing pregnancy and delivery, that is, of the preceding Rh positive 
child; and data relating to the erythroblastotic. 
Personal maternal data analyzed are: 
1. Height (in inches). 
2. Weight (in pounds), before the first pregnancy. 
3. Somatic index, which is height divided by the cube 
root of the weight - this is a useful measure of body type, since, 
for instance, a tall but light woman will have a higher somatic 
index than a shorter, heavier woman. 
1*. Age, at the delivery of the presumed sensitizing 
pregnancy, and 
5. History of abortions, cervical dilatations and curettage. 
Presumed sensitizing pregnancy data analyzed are those 
routinely recorded on the Grace-New Haven Obstetrical Service. These 
data are: 
1. Duration of pregnancy, in days. 
2. Duration of labor, in minutes, 
a. total time elapsed, 
b. first stage, 
c. second stage, 
d. third stage. 
3. Manual /vs. spontaneous placental delivery. 
4. Oxytocics and the third stage of labor, in terms of use 
before and after delivery of the placenta. 
\ 
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5. Rupture of the membranes, 
a. spontaneous vs. artificial, 
b. time of rupture, in minutes, before fetal delivery. 
6. Rectal and vaginal examinations performed during the 
first two stages of labor, 
a. number of rectals, 
b. number of vaginals, 
c. number of rectals plus vaginals. 
7. Duration of general anesthesia at delivery, 
a. nitrous oxide, in minutes, 
b. cyclopropane, 
c. total. 
8. Delivery spontaneous vs. operative. 
To provide quantitation of the extent of the operative pro¬ 
cess, the following arbitrary "Operative Index" is used: 
Elective low forceps . 1 point 
Breech, assisted. 1 point 
Low forceps . 2 points 
Low mid-forceps  3 points 
Low mid-forceps with rotation . h points 
Spontaneous delivery . 0 points 
9. Birth canal lacerations at delivery. 
10. Estimated blood loss at delivery. 
11. Sex. 
12. Birth weight, in grams. 
Data analyzed concerning the erythrob last otic child are 
the following: 
1. Sex. 
2. Birth weight, in grams. 
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3. Physical examination normal, i.e., no signs of erythro¬ 
blastosis fetalis were present; thus the diagnosis was made on the 
basis of laboratory and not clinical data. 
1+. Transfusion required. 
It will be noted that the cases of erythroblastosis fetalis 
in this series may be divided by increasing severity into three groups - 
those with normal physical examinations, those with abnormal physical 
examinations but not requiring transfusion, and those severe enough to 
merit transfusion. 
D. Methods of Study 
Two methods are used - one relating to pathogenesis and one 
to prognosis. 
The study of pathogenesis compares the erythroblastic series 
with the control, by determining in each group mean values, e.g., mater¬ 
nal height, and calculating statistical significance by the t~test. 
An interesting and important aspect of such correlations is 
the necessity for consideration of like subgroups within the total series, 
for significant differences between subgroups may be present in the ab¬ 
sence of such differences for the larger group. "Unless patients with 
a particular disease are divided into comparable groups that are suit¬ 
ably homogenous in clinical properties , as well as in personal and 
in laboratory data, the precision of science is lost.1' ^ To obtain such 
precision in the present study, a number of subgroups are analyzed. 
These include a breakdown by blood types, e.g., type 0 in mother, 
child of the presumed sensitizing pregnancy, and the erythroblastotic. 

-8- 
Because ABO incompatibility is said to protect against the disease, 
the subgroup is considered in which the blood type of either the pre¬ 
sumed sensitizing pregnancy or the erythroblastotic offspring is diff¬ 
erent from the blood type of the mother. 
Also analyzed as subgroups, because of suggestive findings 
within the data, are those with somatic index greater than 13 (12 of 
the 25) and those in which cyclopropane anesthesia was used (10 of 
the 25). 
Evaluation of prognosis, on the other hand, does not involve 
the 'control group1’ at all, but rather considers like cases within 
the series with the disease, noting correlations between severity, 
e.g., whether transfusions were necessary, and the variables under 
consideration, e.g., operative intervention at the presumed sensitizing 
pregnancy. For this analysis, the control population is taken to be 
the remaining cases of the disease. The control for subgroup is 
non-subgroup. Thus, for example (see Table 5-B, page 18) in the group 
of ten patients in which transfusions were done, mean maternal age at 
delivery of the presumed sensitizing pregnancy is 22 years of age. The 
remaining fifteen, where no transfusions occurred, are taken as control- 
these have a mean maternal age at delivery of the presumed sensitizing 
pregnancy of 25 years. These data are then subjected to the t-test for 
statistical significance. 
f'. 
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III. RESULTS 
The data are presented in the following manner: Table 1 shows 
the overall distributions of ABO blood types. Thereafter, the raw 
data are presented on one page (e.g.. Table 2-A) and on the next 
page (e.g., Table 2-B) is the evaluation of these data. 
In order carefully to separate study of the subgroups relating 
to pathogenesis from the subgroups relating to prognosis , in the 
following tables a dotted line separates data referring to each of 
these areas. 
Two abbreviations are employed: 
EF - Erythroblastosis fetalis 
PSP - Presumed sensitizing pregnancy, or the corresponding 
pregnancy in the control series. 
-• 
f- ’ . 
* 
TABLE 1 
ABO BLOOD TYPES 
Case Number Mother Father PSP Child EF Child 
1. A A A A 
2. 0 0 0 0 
3. 0 * 0 0 
h. 0 0 0 
5. 0 0 0 0 
6. A A A A 
7. 0 0 0 0 
8. A A A 
9. B 0 B B 
10. 0 B B B 
11. 0 A A 
12. 0 0 0 
13. 0 0 0 
Ik. A A 0 
15. A A A 
16. 0 A 0 A 
17. A A 0 
18. 0 A A A 
19. 0 0 0 0 
20. A 0 A A 
21. 0 0 0 0 
22. 0 0 0 0 
23. A A A 
2h. A 0 A 0 
25. 0 0 A 
* A "blank space indicates paternal ABO type unknown. 
. 
. 
" 
TABLE 2-A 
Case Number 
1. 
2. 
3. 
1+. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
Ik. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
2l+. 
25- 
MATERNAL HEIGHT 
(in inches) 
EF Series 
65 
62 
66 
59 
65 
66 
65 
65 
65 
61 
68 
62 
6h 
60 
71 
68 
66 
65 
66 
6l 
63 
6U 
69 
68 
Control Series 
65 
67 
61+ 
61+ 
67 
61+ 
61+ 
62 
63 
66 
61+ 
61 
* 
62 
65 
60 
61 
65 
63 
67 
65 
62 
66 
6l 
6l 
* Height not known 
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TABLE 2-B 
Subgroup 
I. All Cases 
II. Maternal 0 
a. PSP 0, EF 0 
b. PSP 0, EF A 
c. PSP A, EF A 
d. PSP 0 or A, EF A 
III. Maternal A 
a. PSP A, EF A 
b. PSP A, EF 0 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 
V. Somatic Index ^13 
VI. Cyclopropane 
Anesthesia 
VII. Physical Examination 
Normal for EF Infant 
MATERNAL HEIGHT 
(in inches) 
EF Series Control Series 
Statistical 
Significance 
Number of Mean Number of Mean 
Cases Value Cases Value n t P^ 
2h 6 5 2k 61+ 1+6 1.025 0.35 
ll+ 61+ lk 61+ 26 insignificant 
9 63 9 61+ 16 0.975 0.35 
2 TO 2 6l 2 5.692 0.01+ 
2 67 2 65 2 2.236 0.20 
k 68 k 63 6 3.652 0.015 
9 65 9 61+ 16 1.365 0.20 
6 61+ 6 65 10 insignificant 
3 67 3 6l 1+ 3.621+ 0.03 
8 6 T 8 63 ll+ 3.228 0.01 
12 66 12 61+ 22 10.029 0.001 
10 6U 10 61+ 18 insignificant 
11 65 15 65 23 insignificant 
9 65 15 65 23 insignificant 
VIII. Transfusion!s) Given 
To EF Infant 
* 
' • • 
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TABLE 3-A 
MATERNAL WEIGHT 
(in pounds, before the first pregnancy) 
Case Number EF Series Control Series 
1. 10 4 117 
2. 115 11*0 
3. 117 13U 
k. 110 170 
5. 127 132 
6. 115 130 
7. 125 106 
8. 131 120 
9. 109 196 
10. 109 ll+2 
11. 169 138 
12. 120 lUo 
13. 1U0 128 
Ik. 113 138 
15. 109 115 
16. 117 117 
IT. 120 115 
18. 130 121 
19. 132 120 
20. 118 1U0 
21. 115 12 k 
22. 115 96 
23. no 156 
2h. 1U0 130 
25. 168 90 
; ; 
r 
-14- 
TABLE 3-B 
MATERNAL WEIGHT 
(in pounds) 
Statistical 
Subgroup EF Series Control Series Significance 
Number of Mean Number of Mean 
Cases Value Cases Value n t P^ 
I. All Cases 25 123 25 130 48 1.280 0.25 
II. Maternal 6 15 127 15 127 28 insignificant 
a. PSP 0, EF 0 10 122 10 129 18 1.051 0.35 
b. PSP 0, EF A 2 lU3 2 10 4 2 1.352 0.35 
c. PSP A, EF A 2 150 2 130 2 0.940 0.45 
d. PSP 0 or A, EF A 4 146 4 117 6 5.630 0.005 
III. Maternal A 9 118 9 129 16 1.874 0.09 
a. PSP A, EF A 6 115 6 130 10 2.006 0.08 
b. PSP A, EF 0 3 124 3 128 4 insignificant 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 
8 133 8 124 l4 0.904 0.40 
V. Somatic Index ^13 12 118 12 133 22 2.032 0.06 
VI. Cyclopropane 
Anesthesia 
11 127 11 136 20 1.280 0.25 
VII. Physical Examination 
Normal for EF Infant 11 122 14 124 23 insignificant 
VIII. Transfusion(s) Given 
to EF Infant 10 122 15 124 23 insignificant 

TABLE 4-A 
MATERNAL SOMATIC INDEX 
(height divided by cube root of weight) 
Case Number EF Series Control Series 
1. 13.82 13.29 
2. 12.75 12.90 
3. 13.49 12.51 
4. 12.32 11.55 
5. 12.93 13.16 
6. 13.57 12.63 
7. 13.00 13.52 
8. 12.80 12.57 
9. 13.60 IO.85 
10. 12.77 12.65 
11. 12.30 12.38 
12. 12.57 11.75, 
13. a 
l4. 13.2b 12.00 
15. 12.56 13.36 
l6. 14.52 12.27 
17. 13.79 12.54 
18. 13.03 13.11 
19. 12.77 12.77 
20. 13.46 12.90 
21. 12.54 13.04 
22. 12.95 13.54 
23. 13.36 12.26 
2b. 13.29 12.04 
25. 12.32 13.61 
* Unable to calculate somatic index, because height not 
known. 
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TABLE 4-B 
MATERNAL SOMATIC INDEX 
Subgroup EF Series Control Series 
Statistical 
Significance 
Number of 
Cases 
Mean 
Value 
Number of 
Cases 
Mean 
Value n t P^ 
I. All Cases 24 13.07 24 12.63 46 1.983 0.06 
II. Maternal 0 14 12.88 14 12.77 26 insignificant 
a. PSP 0, EF 0 9 12.81 9 12.75 16 insignificant 
b. PSP 0, EF A 2 13.42 2 12.94 2 0.373 0.75 
c. PSP A, EF A 2 12.66 2 12.75 2 insignificant 
d. PSP 0 or A, EF A 4 13.04 4 12.84 6 insignificant 
III. Maternal A 9 13.32 9 12.62 16 3.156 0.01 
a. PSP A, EF A 6 13.26 6 12.84 10 1.600 0.15 
b. PSP A, EF 0 3 13.44 3 12.19 4 5.699 0.01 
IV. PSP or EF ABO Type 
Different From 8 13.16 8 12.58 14 1.777 0.10 
Maternal ABO Type 
(V. Somatic Index ^13) 
VI. Cyclopropane 
Anesthesia 10 13.06 10 12.57 18 1.525 0.20 
VII. Physical Examination 
Normal for EF Infant 11 13.06 13 13.09 22 insignificant 
VIII. Transfusion(s) Given 
to EF Infant 9 13.12 15 13.OU 22 insignificant 
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table 5-A 
MATERNAL AGE 
(in years, at delivery of pre¬ 
sumed sensitizing pregnancy) 
Case Number EJ* Series Control Series 
1. 22 20 
2. 21 18 
3. 25 18 
4. 25 33 
5. 31 31 
6. 21 33 
7. 26 24 
8. 33 19 
9. 21 23 
10. 23 29 
11. 22 26 
12. 19 21 
13. 22 20 
14. 30 24 
15. 19 22 
16. 25 25 
IT. 22 31 
18. 26 20 
19. 23 30 
20. 25 26 
21. 25 2T 
22. 2T 20 
23. IT 22 
24. 25 33 
25- 19 19 
4 
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table 5-b 
MATERNAL AGE, IN YEARS, AT DELIVERY 
OF PRESUMED SENSITIZING PREGNANCY 
Subgroup EF Series Control ! Series 
Statistical 
Significance 
Number of 
Cases 
Mean 
Value 
Number of 
Cases 
Mean 
Value n t P^ 
I. All Cases 25 24 25 25 46 0.629 0.55 
II. Maternal 0 15 2h 15 2b 28 insignificant 
a. PSP 0, EF 0 10 2h 10 2b 18 insignificant 
b. PSP 0, EF A 2 22 2 22 2 insignificant 
c. PSP A, EF A 2 2b 2 23 2 insignificant 
d. PSP 0 or A, EF A 4 23 b 23 6 insignificant 
III. Maternal A 9 2b 9 26 16 0.710 0.50 
a. PSP A, EF A 6 23 6 2b 10 insignificant 
b. PSP A, EF 0 3 2 6 3 29 4 1.021 0.40 
IV. PSP or EF ABO Type 
Different From Maternal 8 2b 8 26 l4 0.889 0.40 
ABO Type 
V. Somatic Index ^13 12 2 6 12 25 22 insignificant 
VI. Cyclopropane 
Anesthesia 11 2b 11 25 20 0.020 1.00 
VII. Physical Examination 
Normal for EF Infant 11 24 14 24 23 insignificant 
VIII. Transfusion(s) Given 
to EF Infant 10 22 15 25 23 0.400 0.70 

table 6 
MATERNAL ABORTION, CERVICAL DILATATION. 
AND CURETTAGE (D AND C) HISTORY 
Only cases "with abortions or D and C's are listed. 
Case Number EF Series Control Series 
5. 
13. 
lh. 
19. 
20 
21. 
22. 
2k. 
Abortion, D+C - Before PSP 
Abortion, D+C - after PSP 
Abortion - before PSP 
Abortion - before PSP 
2 Abortions , 1 D+C - all 
before PSP 
Abortion, D+C - after PSP 
Abortion, D+C - after PSP 
Abortion, D+C - after PSP 
By inspection there is no difference between the EF and control series 

TABLE 7-A 
PRESUMED SENSITIZING PREGNANCY: DURATION 
(in days) 
Case Number EF Series Control Series 
1. 270 * 
2. 285 288 
3. 276 260 
4. 273 268 
5. 276 285 
6. 280 283 
7. 283 281 
8. 273 300 
9. 268 295 
10. 292 275 
11. 262 291 
12. 266 282 
13. 265 272 
14. 282 273 
15. 281 282 
16. 279 274 
17. 280 259 
18. 294 291 
19. 288 258 
20. 284 275 
21. 264 267 
22. 306 265 
23. 285 274 
24. 275 262 
25. 284 249 
* Duration of pregnancy not known. 
' 
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TABLE 7-B 
PRESUMED SENSITIZING PREGNANCY: DURATION 
(in days) 
Statistical 
Subgroup EF Series Control Series Significance 
Number of 
Cases 
Mean 
Value 
Number of 
N Cases 
Mean 
Value n t P^ 
I. All Cases 25 279 2k 275 17 1.038 0.35 
II. Maternal 0 15 280 15 275 29 insignificant 
a. PSP 0, EF 0 10 278 10 273 18 1.056 0.35 
b. PSP 0, EF A 2 282 2 268 2 2.077 0.20 
c. PSP A, EF A 2 278 2 291 2 0.081 0.95 
d. PSP 0 or A, EF A k 280 h 280 6 insignificant 
III. Maternal A 9 279 8 276 15 0.622 0.55 
a. PSP A, EF A 6 279 5 283 9 0.791 0.50 
b. PSP A, EF 0 3 279 3 265 h 3.025 0.05 
IV. PSP or EF ABO Type 
Different From 8 281 8 272 lU 1.U61 0.20 
Maternal ABO Type 
V. Somatic Index ^13 12 280 11 275 21 1.116 0.30 
VI. Cyclopropane 
Anesthesia 11 277 10 277 19 insignificant 
VII. Physical Examination 
Normal for EF Infant 11 278 lU 280 23 
VIII. Transfusion(s) Given 
to EF Infant 10 277 15 280 23 
insignificant 
insignificant 

-22- 
TABLE 8-A 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF LABOR - TOTAL TIME~ ELAPSED ~ 
(in minutes) 
Case Number EF Series Control Series 
1. 306 506 
2. 369 280 
3. 857 >+12 
k. 398 332 
5. 300 2.9 k 
6. 531 k2J 
T. 85 175 
8. k2k 727 
9. 209 1+UU 
10. 38? 130 
11. 1013 671 
12. kj2 606 
13. 259 691 
Ik. 535 952 
15- 12^6 52U 
l6. 50U 870 
IT. 771 525 
18. 766 625 
19. 53k 505 
20. 118 329 
21. 303 66k 
22. Uo4 175 
23. 83k 630 
2k. 282 2 40 
25. 915 1095 
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TABLE 8-B 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF LABOR - TOTAL TIME ELAPSED (in minutes) 
Statistical 
Subgroup EF Series 
Number of Mean 
Control 
Number of 
Series 
Mean 
Significance 
Cases Value Cases Value n t P^ 
I. All Cases 25 513 25 513 48 0.004 1.00 
II. Maternal 0 15 504 15 502 28 insignificant 
a. PSP 0, EF 0 10 398 10 413 18 0.172 0.90 
b. PSP 0, EF A 2 710 2 983 2 1.165 0.40 
c. PSP A, EF A 2 890 2 648 2 1.922 0.20 
d. PSP 0 or A, EF A U 800 4 815 6 insignificant 
III. Maternal A 9 56l 9 540 16 insignificant 
a. PSP A, EF A 6 577 6 524 10 0.212 0.85 
b. PSP A, EF 0 3 529 3 572 4 insignificant 
IV. PSP or EF ABO Type 
Different From 8 647 8 639 14 insignificant 
Maternal ABO Type 
V. Somatic Index s*13 12 483 12 511 22 0.324 0.75 
VI. Cyclopropane 
Anesthesia 11 506 11 505 20 insignificant 
VII. Physical Examination 
Normal for EF Infant 11 494 l4 527 23 insignificant 
VIII. Transfusion(s) Given 
to EF Infant 10 554 15 485 23 0.568 0.60 
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TABLE 9-A 
PRESUMED SENSITIZING PREGNANCY: 
DURATION OF FIRST STAGE OF LABOR 
(in minutes) 
Case Number EF Series Control Series 
1. 270 425 
2. 285 180 
3. 805 390 
4. 375 315 
5. 270 282 
6. 450 405 
7. 70 160 
8. 395 690 
9. 180 390 
10. 360 120 
11. 960 630 
12. 435 540 
13. 230 615 
14. 480 945 
15. 1215 495 
16. 420 790 
17. 660 480 
18. 735 555 
19. 520 450 
20. 96 315 
21. 230 630 
22. 360 150 
23. 800 570 
24. 260 180 
25. 840 1050 
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TABLE 9-B 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF FIRST STAGE OF' LABOR" (in minutes) 
Subgroup EF Series 
Number Mean 
Control Series 
Number Mean 
Statistical 
Significance 
of Cases Value of Cases Value n 
I. All Cases 25 1*68 25 1*70 1*8 
II. Maternal 0 15 1*60 15 1*57 28 
a. PSP 0, EF 0 10 358 10 371 18 
b. PSP 0, EF A 2 630 2 920 2 
c. PSP A, EF A 2 81*8 2 593 2 
d. PSP 0 or A, EF A 1* 71*9 1* 756 6 
III. Maternal A 9 511* 9 501 16 
a. PSP A, EF A 6 538 6 1*83 10 
b. PSP A, EF 0 3 1*67 3 535 1+ 
IV. PSP or EF ABO Type 
Different From 8 589 8 591* ll* 
Maternal ABO Type 
V. Somatic Index ^13 12 1*36 12 1*67 22 
VI. Cyclopropane 
Anesthesia 11 1*61 11 1*58 20 
VII. Physical Examination 
Normal for EF Infant 11 1*1*9 ll* 1*83 23 
VIII. Transfusion(s) Given 
to EF Infant 10 502 15 1*1*6 23 
t P^ 
0.027 1.00 
insignificant 
0.157 0.90 
1.171* 0.1*0 
2.150 0.20 
insignificant 
insignificant 
insignificant 
0.272 0.80 
insignificant 
0.279 0.80 
insignificant 
insignificant 
insignificant 
I 
yi 
' . j. 1 V 
• • 
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TABLE 10-A 
PRESUMED SENSITIZING PREGNANCY: 
DURATION OF SECOND STAGE 
(in minutes) 
Case Number EF Series Control Series 
1. 34 79 
2. 83 98 
3. 4o 17 
4. 14 l4 
5. 28 10 
6. 76 21 
T. 11 22 
8. 26 21 
9. 28 52 
10. l6 7 
11. 52 38 
12. 34 62 
13. 27 62 
14. 46 < 6 
15. 30 24 
l6. 83 77 
IT. 105 44 
18. 27 23 
19. 12 52 
20. 26 6 
21. 57 32 
22. 31 15 
23. 30 55 
24. 20 57 
25. 70 43 
. 
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TABLE 10- B 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF SECOND STAGE (in minutes) 
Statistical 
Subgroup EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Value of Cases Value n t Vz. 
I. All Cases 25 hO 25 38 h8 0.385 0.75 
II. Maternal 0 15 39 15 38 28 insignificant 
a. PSP 0, EF 0 10 34 10 38 18 0.406 0.70 
b. PSP 0, EF A 2 77 2 6o 2 0.907 0.50 
c. PSP A, EF A 2 40 2 31 2 0.617 0.60 
d. PSP 0 or A, EF A 1+ 58 h 45 6 0.766 0.50 
III. Maternal A 9 44 9 35 16 0.702 0.50 
a. PSP A, EF A 6 37 6 3h 10 insignificant 
b. PSP A, EF 0 3 57 3 36 4 0.686 0.55 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 8 52 8 37 l4 1.095 0.30 
V. Somatic Index 13 12 hh 12 38 22 0.500 0.65 
VI. Cyclopropane 
Anesthesia 11 39 11 39 20 insignificant 
VII. Physical Examination 
Normal for EF Infant 11 39 14 h2 23 insignificant 
VIII. Transfusion(s) Given 
to EF Infant 10 h9 15 3h 23 1.452 0.20 
. 
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TABLE 11-A 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF THIRD STAGE (in minutes'), 
AND SPONTANEOUS VS. MANUAL DELIVERY OF PLACENTA 
Delivery is spontaneous unless noted otherwise. 
Case Number EF Series Control Series 
1. 
2. 
3. 
4. 
5. 
6. 
T. 
8. 
9. 
10. 
11. 
12. 
2 
1 
12 
9 
2 
5 
4 
3 
1 
11 
1 
3 
13. 
14. 
15. 
16. 
IT. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
2 
9 
1 
1 
6 
4 
2 
2 
l6 
13 
4 
2 
5 
2 
2 
5 
3 
2 
1 
3 
l6 
2 
3 
3 
4 
14 
1 
5 
3 
1 
4?, manual 
3, manual 
8, manual 
2 
10 
5 
3 
2 
By inspection no significant difference exists between the 
EF control and control series for spontaneous vs. manual delivery 
of placenta. 
' 
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TABLE 11-B 
PRESUMED SENSITIZING PREGNANCY: DURATION 
OF THIRD STAGE (in minutes) 
Statistical 
Subgroup EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Value of Cases Value n t P^ 
X All Cases 25 5 25 6 1*8 0.562 0.60 
II, .Maternal 0 15 6 15 T 28 insignificant 
a. PSP 0, EF 0 10 6 10 5 18 0.737 0.50 
b. PSP 0, EF A 2 3 2 3 2 insignificant 
c. PSP A, EF A 2 3 2 25 2 1.020 0.1*5 
d. PSP 0 or A, EF A 1+ 3 1+ 14 6 0.988 0.1*0 
III. Maternal A 9 l* 9 5 16 0.1+85 0.65 
a. PSP A, EF A 6 3 6 6 10 1.1*51* 0.20 
b. PSP A, EF 0 3 6 3 2 1* 1.871+ 0.15 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 8 5 8 8 li* 0.522 0.65 
V. Somatic Index ^13 12 U 12 7 22 0.629 0.55 
VI. Cyclopropane 
Anesthesia 11 6 11 8 20 0.61*9 0.55 
VII. Physical Examination 
Normal for EF Infant 11 7 ll+ 3 23 1.9^9 0.07 
VIII. Transfusion(s) 
Given to EF 10 1* 15 6 23 1.082 0.30 
Infant 
* 
.. 
. 
■ 
. 
. . 
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TABLE 12-A 
PRESUMED SENSITIZING PREGNANCY: 
OXYTOCICS AND THE THIRD STAGE' 
Expressed as time in minutes oxytocic given before or 
after delivery of placenta. "0" means given at time of de¬ 
livery. means given, time not known. A blank space in¬ 
dicates no oxytocic was used. Except as noted otherwise, i.e., 
intravenously (IV), oxytocics were administered intramuscularly. 
Case Number 
PSP: Oxytocics Given Before 
Delivery of Placenta 
PSP: Oxytocics Given After 
Delivery of Placenta 
EF Series Control Series EF Series Control Series 
1. 
2. 
3. 
k. 
5- 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
Ik. 
15. 
16. 
17. 
18. 
19. 
20. 
21 
22. 
23. 
2h. 
25. 
h ? 
7 
2,IV 
? 
1,IV 1 
3,IV 
? 1+ 
1 
Continuous,IV 
? 
1+8,IV 
? 
9 
7 
0 
1 
? 
0 
? 
? 
0 
9 
1 
9 
? 
0 
1 
? 
0 
9 
1 
? 
? 
0 
0 
? 
0 
? 
1 
2 
1 
0 
0 
1 
1 
1 
2 
0 
1 
0 
1 
1 
2 
9 
i ,iv 
2 
0 
1 
0 
0 
Total Number of Cases 8 9 23 2b 
By inspection no significant difference exists between the 
EF and control groups concerning the use of oxytocics after de¬ 
livery of the placenta. 
* 
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TABLE 12-B 
PRESUMED SENSITIZING PREGNANCY: OXYTOCICS 
USED PRECEDING PLACENTAL DELIVERY 
Statistical 
- Subgroup EF Series Control Series Significance 
Total Number of Total Number of 
Number Cases with Number Cases with n t P^ 
of Cases Oxytocics of Cases Oxytocics 
Used Before Used Before 
Placental Placental 
Delivery Delivery 
I. All Cases 25 8 25 9 U8 insignificant 
II. Maternal 0 15 4 15 5 28 insignificant 
a. PSP 0, EF 0 10 h 10 3 18 insignificant 
b. PSP 0, EF A 2 0 2 0 2 • insignificant 
c. PSP A, EF A 2 0 2 1 2 insignificant 
d. PSP 0 or A, 4 0 4 1 6 insignificant 
EF A 
III. Maternal A 9 3 9 3 16 insignificant 
a. PSP A, EF A 6 3 6 2 10 insignificant 
b. PSP A, EF 0 3 0 3 1 it insignificant 
IV. PSP or EF ABO Type 
Different From 8 0 8 3 lit 1.094 0.30 
Maternal ABO Type 
V. Somatic Index ^13 12 2 12 5 22 1.342 0.20 
VI. Cyclopropane 
Anesthesia 11 4 11 It 20 insignificant 
VII. Physical Examina- 
tion Normal for 11 3 l4 5 23 insignificant 
EF Infant 
VIII. Transfusion(s) 
Given to EF 10 3 15 5 23 insignificant 
Infant 
■ 
r r 
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TABLE 13-A 
PRESUMED SENSITIZING PREGNANCY: RUPTURE 
OF MEMBRANES - SPONTANEOUS VS. ARTIFICIAL 
Case Number EF Series Control Series 
Spontaneous Artificial Spontaneous Artificial 
1. X X 
2. X X 
3. X X 
k. X X 
5. X X 
6. X X 
7. X X 
8. X X 
9. X X 
10. X X 
11. X X 
12. X X 
13. X X 
lh. X X 
15. X X 
16. X X 
17. X X 
18. X X 
19. 
* * X 
20. X X 
21. X * 
22. X X 
23. X X 
2h. X X 
25. X X 
Total Number of Cases 9 15 13 11 
* Not known 
. 
-• 
■ 
_ 
. 
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TABLE 13-B 
PRESUMED SENSITIZING PREGNANCY: RUPTURE 
OF MEMBRANES - SPONTANEOUS VS. ARTIFICIAL 
Statistical 
Subgroup EF Series Control Series Significance 
Total Number of Total Number of 
Number Cases with Number Cases with n t p^ 
of Cases Spontaneous of Cases Spontaneous 
Rupture of Rupture of 
Membranes Membranes 
I. All Cases 24 9 2h 13 46 1.151 0.30 
II. Maternal 0 Ik k lh 8 26 1.537 0.15 
a. PSP 0, EF 0 9 3 9 T 16 2.108 0.06 
b. PSP 0, EF A 2 0 2 0 2 insignificant 
c. PSP A, EF A 2 0 2 1 2 insignificant 
d. PSP 0 or A, h 0 k 1 6 insignificant 
EF A 
III. Maternal A 9 k 9 5 16 insignificant 
a. PSP A, EF A 6 3 6 3 10 insignificant 
b. PSP A, EF 0 3 1 3 2 4 insignificant 
IV. PSP or EF ABO Type 
Different from 8 2 8 3 14 insignificant 
Maternal ABO Type 
V. Somatic Index 5-13 12 5 12 6 22 insignificant 
VI. Cyclopropane 
0.628 0.55 Anesthesia 11 5 10 6 19 
VII. Physical Examina¬ 
tion Normal for 11 
EF Infant 
5 14 9 23 0.480 0.65 
VIII. Transfusion(s) 
Given to EF 10 3 15 6 23 insignificant 
Infant 

TABLE 14-A 
PRESUMED SENSITIZING PREGNANCY: TIME 
ELAPSED (in minutes) FROM RUPTURE 
OF~ MEMBRANES UNTIL DELIVERY OF INFANT 
Case Number EF Series Control Series 
1. 64 128 
2. 23 248 
3. 745 452 
4. 26 509 
5- 13 67 
6. 121 201 
7. 81 12 
8. 4o6 6 
9. 208 7 
10. 46 3 
11. 232 323 
12. 49 572 
13. 47 12 
ll+. 216 1 
15. 435 25 
16. * 102 
17. 255 1784 
18. 992 308 
19. 23 1282 
20. 32 6 
21. 407 
22. 221 40 
23. 223 65 
24. 20 27 
25. 295 28 
* Not known 
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I. 
II. 
III. 
IV. 
V. 
VI. 
VII. 
VIII. 
TABLE ll+-B 
PRESUMED SENSITIZING PREGNANCY: TIME 
ELAPSED (in minutes) FROM RUPTURE 
OF MEMBRANES UNTIL DELIVERY OF INFANT 
Statistical 
Subgroup EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Time of Cases Time n t P^ 
Elapsed Elapsed 
All Cases 2k 216 2k 259 k6 0.1*19 0.70 
Maternal 0 Ik 229 lk 283 26 insignificant 
a. PSP 0, EF 0 10 l6h 9 355 17 1.350 0.20 
b. PSP 0, EF A 1 295 2 65 1 3.59k 0.20 
c. PSP A, EF A 2 612 2 316 2 0.769 0.55 
d. PSP 0 or A, 3 506 k 190 5 1.1*25 0.25 
EF A 
Maternal A 9 197 9 2k9 16 0.278 0.80 
a. PSP A, EF A 6 2.1k 6 72 10 1.825 0.01 
b. PSP A, EF 0 3 16k 3 6 Ok k 0.71*1 0.50 
PSP or EF ABO Type 
Different from 
Maternal ABO Type 
T 29 k 8 322 13 0.110 0.95 
Somatic Index ^13 11 269 12 265 21 insignificant 
Cyclopropane 
Anesthesia 11 2kk 10 32U 19 0.1*31* 0.70 
Physical Examina¬ 
tion Normal EF 
Infant 
11 198 13 231 22 insignificant 
Transfusion(s) 
Given to EF 9 172 15 2l*2 23 0.701* 0.50 
Infant 
■ 
. 
■ . 
' 
. 
. 
• 
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TABLE 15-A 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
OF RECTAL EXAMINATIONS PERFORMED 
DURING THE FIRST TWO STAGES 
Case Number EF Series Control Series 
1. 3 6 
2. 1 5 
3. 4 5 
4. 1 4 
5. 3 3 
6. 5 4 
T. 0 2 
8. 4 6 
9. 3 4 
10. 5 3 
11. T 2 
12. 1 2 
13. 2 4 
l4. 2 2 
15- 6 4 
16. 5 4 
IT. 11 3 
18. 4 3 
19. 6 4 
20. 0 3 
21. 3 3 
22. 5 1 
23. 5 2 
24. 3 3 
25. 4 1 
- 
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TABLE 15-B 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
Subgroup 
I. All Cases 
II. Maternal 0 
a. PSP 0, EF 0 
b. PSP 0, EF A 
c. PSP A, EF A 
d. PSP 0 or A, 
EF A 
III. Maternal A 
a. PSP A, EF A 
b. PSP A, EF 0 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 
8 5.1 8 2.6 14 2.400 0.04 
V. Somatic Index s»13 12 3.8 12 3.4 22 insignificant 
VI. Cyclopropane 
Anesthesia 11 4.3 11 3.2 20 1.181 0.30 
VII. Physical Examina¬ 
tion Normal for 
EF Infant 
11 3.8 lli 3.6 23 insignificant 
VIII. Transfusion(s) 
Given to EF 10 3.7 15 3.7 23 insignificant 
Infant 
OF RECTAL EXAMINATIONS PERFORMED 
DURING THE FIRST TWO STAGES 
Statistical 
EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Number of Cases Number n t P^ 
of Rectal of Rectal 
Examinations Examinations 
25 3.7 25 3.3 48 0.721 0.50 
15 3.4 15 3.1 28 insignificant 
10 2.6 10 3.3 18 0.270 0.80 
2 4.5 2 2.5 2 1.265 0.35 
2 5-5 2 2.5 2 1.898 0.20 
4 5-0 4 2.5 6 8.257 0.001 
9 4.3 9 3.7 16 insignificant 
6 3.8 6 4.2 10 insignificant 
3 5.3 3 2.7 4 0.930 0.45 
' 
4 : • 
■ 
- 
- 
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TABLE 16-A 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
OF VAGINAL EXAMINATIONS PERFORMED 
DURING THE FIRST TWO ^STAGES 
Only cases with vaginal examinations are listed. 
Case Number EF Series Control Series 
2. 1 1 
3. 1 
k. 1 
7. 1 
10. 1 1 
Ik. 2 
15. 1 
16. 1 
18. 2 
22. 1 
23. 1 
25. 1 
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TABLE 16-B 
I. 
II. 
III. 
IV. 
V. 
VI. 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
OF VAGINAL EXAMINATIONS PERFORMED 
DURING THE FIRST TWO STAGES 
Statistical 
Subgroup EF Series 
Number Mean 
Control 
Number 
Series 
Mean 
Significance 
of Cases Number 
of Vaginal 
Examinations 
of Cases Number 
of Vaginal 
Examinations 
n t P^ 
All Cases 25 0.4 25 0.2 48 1.562 0.14 
Maternal 0 15 0.5 15 0.3 28 0.650 0.55 
a. PSP 0, EF 0 10 0.5 10 0.1 18 2.058 0.06 
b. PSP 0, EF A 2 4.5 2 2.5 2 1.265 0.35 
c. PSP A, EF A 2 5-5 2 2.5 2 1.898 0.20 
d. PSP 0 or A, 
EF A 
4 0.3 4 0.8 6 insignificant 
Maternal A 9 0.4 9 0 16 1.835 0.09 
a. PSP A, EF A 6 0.3 6 0 10 insignificant 
b. PSP A, EF 0 3 0.7 3 0 4 3.162 0.04 
PSP or EF ABO Type 
Different From 
Maternal ABO Type 
8 0.5 8 0.5 14 insignificant 
Somatic Index ^13 12 0.4 12 0.3 22 insignificant 
Cyclopropane 
Anesthesia 11 0.3 11 0.2 20 0.392 0.70 
VII. Physical Examination 
Normal for EF 11 0.5 l4 0.4 23 insignificant 
Infant 
VIII. Transfusion(s) 
Given To 10 0.5 15 0*4 23 insignificant 
EF Infant 
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TABLE 1T-A 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
OF RECTAL PLUS VAGINAL EXAMINATIONS 
PERFORMED DURING THE FIRST TWO STAGES 
Case Number EF Series Control Series 
1. 3 6 
2. 2 6 
3. 5 5 
k. 2 k 
5. 3 3 
6. 5 4 
7. 1 2 
8. k 6 
9. 3 k 
10. 6 k 
11. 7 2 
12. 1 2 
13. 2 k 
lU. k 2 
15. 7 k 
16. 5 5 
17. 11 3 
18. k 5 
19. 6 h 
20. 0 3 
21. 3 3 
22. 6 1 
23. 6 2 
2k. 3 3 
25. 5 1 
* ' 
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TABLE 1T-B 
PRESUMED SENSITIZING PREGNANCY: NUMBER 
OF RECTAL PLUS VAGINAL EXAMINATIONS 
PERFORMED DURING THE FIRST TWO STAGES 
Statistical 
Subgroup EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Number of of Cases Number of n t P^ 
Examinations Examinations 
I. All Cases 25 4.2 25 3.5 48 1.139 0.30 
II. Maternal 0 15 3.9 15 3.4 28 insignificant 
a. PSP 0, EF 0 10 3.1 10 3.4 18 0.090 0.95 
b. PSP 0, EF A 2 5-0 2 3.0 2 1.000 0.45 
c. PSP A, EF A 2 5.5 2 3.5 2 1.333 0.35 
d. PSP 0 or A, 4 5.3 4 3.3 6 1.656 0.20 
EF A 
III. Maternal A 9 4.8 9 3.7 l6 0.975 0.35 
a. PSP A, EF A 6 4.2 6 4.2 10 insignificant 
b. PSP A, EF 0 3 6.0 3 2.7 4 1.313 0.30 
IV. PSP or EF ABO Type 
Different From 8 5.6 8 3.1 14 2.441 0.04 
Maternal ABO Type 
V. Somatic Index i-13 12 4.2 12 3.7 22 0.562 0.60 
VI. Cyclopropane 
Anesthesia 11 4.5 11 3.4 20 1.270 0.25 
VII. Physical Examina- 
tion Normal for 11 4.4 14 4.0 23 insignificant 
EF Infant 
VIII. Transfusion(s) 
Given To 10 4.2 15 4.1 23 insignificant 
EF Infant 
■ 
TABLE 18-A 
PRESUMED SENSITIZING PREGNANCY: NITROUS OXIDE 
ANESTHESIA-DURATION (in minutes) 
Case Number EF Series Control Series 
1. 15 65 
2. 15 25 
3. 10 !5; 
4. 5 
5. 2 10 
6. 20 
7. 30 15 
8. 5 
9. 10 10 
10. 55 
11. 5 25 
12. 20 20 
13. 14 20 
l4. 30 15 
15- 10 10 
l6. 45 
17. 15 
18. 15 15 
19. 25 25 
20. 15 10 
21, 20 
22. 10 15 
23. 25 12 
24. 15 
25. 25 25 
* Blank space indicates nitrous oxide anesthesia was not 
used, or was but duration of use is not known. 

TABLE 18-B 
PRESUMED SENSITIZING PREGNANCY: NITROUS OXIDE 
ANESTHESIA'DURATION (in minutes) 
Statistical 
Subgroup EF Series Control Series Significance 
Number Duration Number Duration 
of Cases of Nitrous of Cases of Nitrous n t P^ 
Oxide Oxide 
Anesthesia Anesthesia 
I. All Cases 21 18 21 20 h0 0.666 0.55 
II. Maternal 0 14 18 12 21 2h insignificant 
a. PSP 0, EF 0 10 15 8 18 16 0.909 G.40 
b. PSP 0, EF A 1 25 2 35 1 0.577 0.70 
c. PSP A, EF A 2 10 2 20 2 1.4l4 0.30 
d. PSP 0 or A, 3 15 4 28 5 1.409 0.25 
EF A 
III. Maternal A 6 18 8 20 12 insignificant 
a. PSP A, EF A 4 l6 6 20 8 0.349 0.75 
b. PSP A, EF 0 2 23 2 15 2 1.000 0.45 
IV. PSP or EF ABO Type 
Different From 6 24 6 23 10 insignificant 
Maternal ABO Type 
V. Somatic Index ^13 9 18 10 22 17 0.510 0.65 
VI. Cyclopropane 
Anesthesia 10 12 15 18 23 1.521 0.15 
VII. Physical Examina- 
tion Normal 10 20 11 15 19 insignificant 
For EF Infant 
VIII. Transfusion(s) 
Given to 8 l4 13 20 21 1.287 0.25 
EF Infant 
. 
. 
•- ' 
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PRESUMED 
TABLE 19-A 
SENSITIZING PREGNANCY: CYCLOPROPANE 
ANESTHESIA-DURATION (in minutes) 
Case Number EF Series Control Series 
1. 20 
* 
2. 15 
3. 25 
if. 15 
5. 3 20 
6. 
7. 
8. 15 
9. 10 10 
10. 
11. 10 10 
12. 20 
13. 6 
14. 15 
15. 10 
l6. 15 
17. 
18. 22 20 
19. 10 
20. 
21. 5 
22. 10 
23. 10 13 
24 15 
25. 20 
* Blank space indicates cyclopropane anesthesia was not 
used, or was but duration of use is not known. 

TABLE 19-B 
PRESUMED SENSITIZING PREGNANCY; CYCLOPROPANE 
ANESTHESIA - DURATION (in minutes) 
Subgroup EF Series Control Series 
Statistical 
Significance 
Number Cyclopropane Number Cyclopropane 
of Cases Anesthesia of Cases Anesthesia n t p^ 
Duration Duration 
I. All Cases 10 11 16 16 24 2.130 0.05 
II. Maternal 0 T 10 9 18 Ik 3.007 0.01 
a. PSP 0, EF 0 5 8 5 20 8 4.598 0.005 
b. PSP 0, EF A 0 - 2 18 0 - 
c. PSP A, EF A 2 16 2 15 2 insignificant 
d. PSP 0* or A, 2 16 1+ 16 4 insignificant 
EF A 
III. Maternal A 2 15 6 13 6 0.671 0.55 
a. PSP A, EF A 2 15 4 12 h 0.840 0.50 
b. PSP A, EF 0 0 - 2 15 0 - 
IV. PSP or EF ABO Type 
Different From 2 16 6 16 6 insignificant 
Maternal ABO Type 
V. Somatic Index ^-13 4 16 8 15 10 insignificant 
(VI. Cyclopropane 
Anesthesia) 
VII. Physical Examina¬ 
tion Normal for 5 11 
EF Infant 
VIII. Transfusion(s) 
Given To 4 9 
EF Infant 
5 12 8 insignificant 
6 13 8 insignificant 
' 
. . . 
■ 
. 
TABLE 20-A 
PRESUMED SENSITIZING PREGNANCY: 
ANESTHESIA-TOTAL DURATION (in minutes) 
Case Number EF Series Control Series 
1. 35 65 
2. 15 IfO 
3. 10 U0 
k. 20 
5. 5 30 
6. 20 
7. 30 15 
8. 20 
9. 20 20 
10. 55 35 
11. 15 35 
12. 20 Uo 
13. 20 20 
lU. 30 30 
15. 10 20 
16. 6o 
17. 75 15 
18. 37 50 
19. 25 25 
20 15 20 
21. 25 75 
22. 20 15 
23. 35 25 
2k. 15 15 
25. 25 k5 
* Blank space indicates general anesthesia was not used, 
or was but duration of use is not known. 

TABLE 20-B 
I. 
II. 
III. 
IV. 
V. 
(VI. 
VII. 
VIII. 
PRESUMED SENSITIZING PREGNANCY: ANESTHESIA - 
TOTAL DURATION (in minutes) 
Statistical 
Subgroup EF Series 
Number Duration 
Control 
Number 
Series 
Duration 
Significance 
of Cases of 
Anesthesia 
of Cases of 
Anesthesia 
n t P^ 
All Cases 22 26 2b 33 44 1.460 0.20 
Maternal 0 l4 23 lb 39 26 3.466 0.005 
a. PSP 0, EF 0 10 19 9 36 17 3.328 0.01 
b. PSP 0, EF A 1 25 2 53 1 2.086 0.30 
c. PSP A, EF A 2 26 2 43 2 1.239 0.35 
d. PSP 0 or A, 
EF A 
3 26 b 48 5 2.683 0.05 
Maternal A T 31 9 26 lb 0.550 0.60 
a. PSP A, EF A 4 2k 6 28 8 0.433 0.70 
b. PSP A, EF 0 3 ho 3 20 b 1.069 0.35 
PSP or EF ABO Type 
Different From 
Maternal .ABO Type 
7 36 8 36 13 insignificant 
Somatic Index ^13 10 30 11 32 19 insignificant 
Cyclopropane 
Anesthesia) 
Physical Examina¬ 
tion Normal 11 30 11 21 20 1.435 0.20 
For EF Infant 
Transfusion(s) 
Given to EF 8 19 l4 29 20 1.532 0.15 
Infant 
* 
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TABLE 21-A 
PRESUMED SENSITIZING PREGNANCY: DELIVERY 
SPONTANEOUS VS. OPERATIVE. "OPERATIVE INDEX". 
"Operative index" arbitrarily defined as follows: Elective 
low forceps 1 point; Breech, assisted, 1 point; low forceps, 2 
points; low mid forceps, 3 points; low mid forceps with rotation, 
U points; spontaneous delivery, no points. 
Case Number EF Series Control Series 
1. 1 k 
2. 1 2 
3. 0 1 
k. 0 0 
5. 0 0 
6. 0 0 
7. 0 1 
8. 0 1 
9. 1 2 
10. 1 1 
11. 1 0 
12. h k 
13. 1 0 
14. 3 2 
15. 3 1 
16. 1 
17. 1 0 
18. 2 1 
19. 0 1* 
20. 0 0 
21. 2 2 
22. 3 0 
23. 1 0 
2k. 0 1 
25. 1 1 

TABLE 21-B 
-1+9- 
PRESUMED SENSITIZING PREGNANCY: 
DELIVERY SPONTANEOUS VS. OPERATIVE 
Statistical 
Subgroup EF Series Control Series 
Number Mean Number Mean 
of Cases "Operative of Cases "Operative n t P^ 
Index" Index" 
I. All Cases 25 1.1 25 1.3 1+8 0.1+1+5 0.70 
II. Maternal 0 15 1.1 15 1.1+ 28 0.539 0.60 
a. PSP 0, EF 0 10 1.1 10 1.1+ 18 0.1+1+3 0.70 
b. PSP 0, EF A 2 1.0 2 2.5 2 1.000 0.20 
c. PSP A, EF A 2 1.5 1+ 0.5 2 2.000 0.20 
d. PSP 0 * or A, 1+ 1.3 1+ 1.5 6 insignificant 
EF A 
III. Maternal A 9 1.0 9 1.0 16 insignificant 
a. PSP A, EF A 6 0.8 6 1.0 10 insignificant 
b. PSP A, EF 0 3 1.3 3 1.0 1+ insignificant 
IV. PSP or EF ABO Type 
Different From 8 1.3 8 1.3 ii+ insignificant 
Maternal ABO Type 
V. Somatic Index ^13 12 0.8 12 1.3 22 1.1+L5 0.20 
VI. Cyclopropane 
Anesthesia 11 1.2 11 0.8 20 O.T59 0.50 
VII. Physical Examina¬ 
tion Normal 
For EF Infant 
11 0.5 ll+ 
10* 
1.1+ 
1.8* 
23 
19* 
1.870 
2.565* 
0.08 
0.02 
VIII. Transfusion(s) 
Given To 
EF Infant 
10 1.8 15 0.6 23 1.359 0.20 
* Control taken as the 10 cases in which the EF infant received transfusion(s). 
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TABLE 22 
PRESUMED SENSITIZING PREGNANCY: 
BIRTH"CANAL LACERATIONS AT DELIVERY 
Only cases with lacerations are listed. 
Case Number EF Series Control Series 
9. 3° extension of 
episiotomy. 
12. 2 cm. left sulcus 
laceration. 
16. shallow right left sulcus lacera- 
sulcus Iceration. tion. 
IT. 2 inch cervical 
laceration. 
23. deep vaginal tear, 
2° laceration. ir\
 
CM
 
episiotomy ex¬ 
tension to right 
fornix. 
U° laceration. 
By inspection there is no difference between the EF and 
control series. 
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table 2 3-A 
PRESUMED SENSITIZING PREGNANCY; ESTIMATED 
BLOOD LOSS (in cubic centimeters) AT DELIVERY 
Case Number EF Series Control Series 
1. HOO 100 
2. 300 300 
3. 200 300 
k. 200 200 
5. 200 200 
6. 300 275 
7. 300 100 
8. 150 200 
9. 200 200 
10. 100 150 
11. 250 300 
12. 200 200 
13. 150 200 
Ik. 300 200 
15. 250 200 
16. 150 loo 
17. 375 75 
18. 350 Uoo 
19. 50 250 
20. 175 100 
21. 100 250 
22. 100 200 
23. 250 300 
2k. 200 150 
25. kOO 300 
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I. 
II. 
III. 
IV. 
V. 
VI. 
VII. 
VIII. 
TABLE 23-B 
PRESUMED SENSITIZING PREGNANCY: ESTIMATED BLOOD 
LOSS (in cubic centimeters) AT DELIVERY 
Subgroup 
All Cases 
Maternal 0 
a. PSP 0, EF 0 
b. PSP 0, EF A 
c. PSP A, EF A 
d. PSP 0 or A, 
EF A 
Maternal A 
a. PSP A, EF A 
b. PSP A, EF 0 
PSP or EF ABO Type 
Different From 
Maternal ABO Type 
Somatic Index 5;13 
Cyclopropane 
Anesthesia 
Physical Examina¬ 
tion Normal For 
EF Infant 
Transfusion(s) 
Given to EF 
Infant 
EF Series 
Number Estimated 
of Cases Blood 
Loss 
25 226 
15 203 
10 180 
2 225 
2 300 
k 288 
9 267 
6 25*t 
3 292 
8 266 
12 26? 
11 23^ 
11 2kQ 
10 220 
Control Series 
Number Estimated 
of Cases Blood 
Loss 
25 222 
15 250 
10 220 
2 350 
2 350 
it 350 
9 178 
6 196 
3 li+2 
8 2U7 
12 217 
11 220 
lit 209 
15 230 
Statistical 
Significance 
n t P^ 
it8 0.15it 0.90 
28 1.37it 0.20 
18 1.251 0.25 
2 0.928 0.50 
2 0.707 0.60 
6 1.000 O.itO 
16 2.29 it o.o4 
10 1.159 0.30 
it 2. itO 5 0.08 
lit insignificant 
22 1.209 0.25 
20 insignificant 
23 insignificant 
23 insignificant 
• 
. 
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TABLE 24-A 
PRESUMED SENSITIZING PREGNANCY: 
SEX OF<CHILD 
Case Number EF Series 
Male Female 
Control Series 
Male Female 
1. 
2. 
3. 
4. 
5. 
6. 
T. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15- 
16. 
IT. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
x 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
. ■ 
TABLE 2b-B 
PRESUMED SENSITIZING PREGNANCY: 
SEX OF CHILD 
Statistical 
Subgroup EF Series Control Series Significance 
Number Percent Number Percent 
of Cases with Male of Cases with Male n t Pz 
Children Children 
I. All Cases 25 68% 25 52% 48 1.147 0.30 
II. Maternal 0 15 47% 15 40% 28 insignificant 
a. PSP 0, EF 0 10 50% 10 40% 18 insignificant 
b. PSP 0, EF A 2 100% 2 50% 2 insignificant 
c. PSP A, EF A 2 0% 2 0% 2 insignificant 
d. PSP 0 or A, b 50% 1+ 25% 6 insignificant 
EF A 
III. Maternal A 9 89% 9 78%* 16 insignificant 
a. PSP A, EF A 6 83% 6 83% 10 insignificant 
b. PSP A, EF 0 3 100% 3 67% b insignificant 
IV. PSP or EF ABO Tjrpe 
Different From 8 75% 8 50% lb insignificant 
Maternal ABO Type 
V. Somatic Index ^13 12 83% 12 50% 22 2.000 0.06 
VI. Cyclopropane 
Anesthesia 11 45% 11 55% 20 insignificant 
VII. Physical Examina¬ 
tion Normal For 11 54% l4 
EF Infant 
VIII. Transfusion(s) 
Given to EF 15 67% 10 
Infant 
79% 23 insignificant 
TO% 23 insignificant 
* Were the control value the expected 50%, P would he <'0.09, i.e., not significant. 
■ 
. 
- 
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table 25-A 
PRESUMED SENSITIZING PREGNANCY: 
BIRTH WEIGHT OF CHILD (in grams) 
Case Number EF Series Control Series 
1. 2990 3748 
2. 3590 3995 
3. 2885 3985 
4. 3755 4350 
5. 2960 3355 
6. 3725 3150 
7. 4000 2410 
8. 3695 3820 
9. 2240 2480 
10. 3390 3405 
11. 3030 3510 
12. 3405 3480 
13. 3180 2830 
Ik. 4015 3280 
15. 4090 3355 
16. 3810 3275 
17. 3090 2795 
18. 3345 3165 
19. 3275 3415 
20. 3750 2410 
21. 2705 2730 
22. 3505 3420 
23. 2745 3055 
2k. 3985 3220 
25. 4080 1945 
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table 25-B 
PRESUMED SENSITIZING PREGNANCY: 
BIRTH WEIGHT OF CHILD (in grams) 
Statistical 
Subgroup EF Series Control Series Significance 
Number Mean Number Mean 
of Cases Weight of Cases Weight n t P^ 
of Child of Child 
I. All Cases 25 3410 25 3223 48 0.040 1.00 
II. Maternal 0 15 3394 15 3285 28 insignificant 
a. PSP 0, EF 0 10 3326 10 3397 18 insignificant 
b. PSP 0, EF A 2 3945 2 2610 2 1.699 0.25 
c. PSP A, EF A 2 3188 2 3338 2 0.091 0.95 
d. PSP 0 or A, 4 3566 4 2974 6 1.405 0.25 
EF A 
III. Maternal A 9 3565 9 3204 16 1.642 0.15 
a. PSP A, EF A 6 3499 6 3256 10 0.814 0.45 
b. PSP A, EF 0 3 3697 3 3098 4 1.761 0.20 
IV. PSP or EF ABO Type 
Different From 8 3593 8 3074 14 2.207 0.05 
Maternal ABO Type 
V. Somatic Index ^13 12 3382 12 3080 22 1.352 0.20 
VI. Cyclopropane 
Anesthesia 11 3050 11 3222 20 0.847 0.45 
VII. Physical Examina¬ 
tion Normal For 
EF Infant 
11 3326 14 3475 23 insignificant 
VIII. Transfusion(s) 
Given to EF 10 3459 15 3377 23 insignificant 
Infant 
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table 26-A 
ERYTHROBLASTOSIS FETALIS: 
SEX OF CHILD 
Control is sex of corresponding non-erythroblastotic child. 
Case Number EF Series Control Series 
Male Female Male Female 
1. X X 
2. X X 
3. X X 
k. X X 
5. X X 
6. X X 
7. X X 
8. X X 
9. X X 
10. X X 
11. X X 
12. X X 
13. X X 
Ih. X X 
15. X X 
16. X X 
17. X X 
18. X X 
19. X X 
20. X X 
21. X X 
22. X X 
23. X X 
2h. X X 
25. X X 
. 
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table 26-b 
ERYTHROBLASTOSIS FETALIS: 
SEX OF CHILD 
Statistical 
Subgroup EF Series 
Number Percent 
Control 
Number 
Series 
Percent 
Significance 
of Cases with Male 
Children 
of Cases with Male 
Children 
n t P<£ 
I. All Cases 25 k8% 25 hh% k8 insignificant 
II. Maternal 0 15 kl% 15 kl% 28 insignificant 
a. PSP 0, EF 0 10 10% 10 k0% 18 1.3U2 0.20 
b. PSP 0, EF A 2 0% 2 100% 1* 0.15* 
C. PSP A, EF A 2 0% 2 0% 2 insignificant 
d. PSP 0fc or A, 
EF A 
U 0% k 50% 6 1.732 0.15 
III. Maternal A 9 hk% 9 33% 16 insignificant 
a. PSP A, EF A 6 50% 6 33% 10 insignificant 
b. PSP A, EF 0 3 33% 3 33% k insignificant 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 
8 13% 8 50% ik 1.655 015 
V. Somatic Index ^13 12 50% 12 25% 22 1.25k 0.25 
VI. Cyclopropane 
Anesthesia 11 b5% 11 55% 20 insignificant 
VII. Physical Examina¬ 
tion Normal For 
EF Infant 
11 36% Ik 51% 23 1.307 0.25 
VIII. Transfusion(s) 
Given To EF 10 60% 15 ko% 23 0.91k 0.35 
Infant 
* t-test not applicable (s2 = 0). By chi square testing, n=l, chi square= 2, P^0.15 
- t 
. 
V 
■ 
■ 
: 
■ 
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TABLE 27-A 
ERYTHROBLASTOSIS FETALIS; 
BIRTH WEIGHT OF CHILD 
(in grams) 
Control is weight of corresponding non-erythroblastotic child. 
Case Number EF Series Control Series 
1. 3285 2900 
2. 4o8o 3475 
3. 2665 4120 
4. 3775 4415 
5. 3020 3945 
6. 3950 3600 
7. 3350 2835 
8. 2065 3425 
9. 1800 2335 
10. 3155 3155 
11. 2300 3265 
12. 3140 3400 
13. 3230 4085 
14. 2940 3405 
15. 3125 3575 
16. 3375 3180 
17. 2300 3360 
18. 3860 2890 
19. 3810 3355 
20. 3210 2680 
21. 2520 3360 
22. 3000 3575 
23. 3015 3075 
24. 4l8o 3615 
25- 4360 2865 
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table 27-B 
ERYTHROBLASTOSIS FETALIS: 
Subgroup 
BIRTH WEIGHT OF CHILD 
EF Series 
(in grams' 
Control 
) 
Series 
Statistical 
Significance 
Number Mean Number Mean 
of Cases Weight of Cases Weight 
of Child of Child n t PjL 
I. All Cases 25 3180 25 3353 1+8 1.053 0.30 
II. Maternal 0 15 3309 15 3^01 28 0.776 0.50 
a. PSP 0, EF 0 10 3259 10 3657 18 1.817 0.09 
b. PSP 0, EF A 2 3868 2 3023 2 1.175 0.1+0 
c. PSP A, EF A 2 3080 2 3078 2 insignificant 
d. PSP 0 or A, 
EF A 
k 3W h 3050 6 0.937 o.i+o 
III. Maternal A 9 3119 9 3293 16 0.690 0.50 
a. PSP A, EF A 6 3108 6 3209 10 insignificant 
b. PSP A, EF 0 3 31*+0 3 3U60 1+ 0.57!+ 0.60 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 
8 3309 8 3161 ll+ 0.515 0.65 
V. Somatic Index ^13 12 3161 12 3166 22 insignificant 
VI. Cyclopropane 
Anesthesia 11 2919 11 3382 20 1.758 0.10 
VII. Physical Examina¬ 
tion Normal For 11 3239 lU 3135 23 insignificant 
EF Infant 
VIII. Transfusion(s) 
Given to EF 10 309*+ 15 3238 23 0.522 0.65 
Infant 
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TABLE 28-A 
ERYTHROBLASTOSIS FETALIS: CASES WITH 
NORMAL NEONATAL PHYSICAL EXAMINATIONS 
''Normal" here defined as "no signs of erythroblastosis 
fetalis were present." 
Only cases with normal physicals are listed. 
Case Number Normal Physi* 
1. X 
3. X 
A. X 
5- X 
7. X 
10. X 
17. X 
21. X 
23. X 
2b. X 
25. X 
Note that in Tables 28-B and 29-B each control series con¬ 
sists of the remaining cases; for instance, the 15 "Maternal 0" 
cases are controlled by the 10 cases for which the maternal ABO 
type is not 0. 
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TABLE 28-B 
ERYTHROBLASTOSIS FETALIS: CASES WITH 
NORMAL NEONATAL PHYSICAL EXAMINATIONS 
Subgroup Cases Within Control: Statistical 
The Subgroup 
Number Percent 
Remaining Cases 
Number Percent 
Significance 
of Cases with Normal 
Physical 
Examinations 
of Cases with Normal 
Physical 
Examinations 
n t P^ 
I. All Cases 25 bk% - - - - 
II. Maternal 0 15 bl% 10 b0% 23 insignificant 
a. PSP 0, EF 0 10 50% 15 b0% 23 0.176 0.65 
b. PSP 0, EF A 2 50% 23 b3% 23 0.017 1.00 
c. PSP A, EF A 2 0% 23 k8% 23 1.299 0.25 
d. PSP 0 or A, 1 25% 21 k8% 23 0.812 0.15 
EF A 
III. Maternal A 9 hh% 16 kb% 23 insignificant 
a. PSP A, EF A 6 33% 19 bl% 23 insignificant 
b. PSP A, EF 0 3 61% 22 bl% 23 0.818 0.15 
IV. PSP or EF ABO Type 
Different From 
Maternal ABO Type 8 50% IT hl% 23 insignificant 
V. Somatic Index ^13 12 50% 13 38% 23 O.5I8 0.60 
VI. Cyclopropane 
Anesthesia 11 55% lk 36% 23 0.895 o.lo 
I 
. 
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table 29-A 
ERYTHROBLASTOSIS FETALIS: 
TRANSFUSION GIVEN 
Only cases in which transfusion was administered are listed. 
Case Number Number of Transfusions Given 
2. 1 
6. 1 
9. 2 
11. 1 
12. 2 
13. 2 
Ik. 1 
15. 1 
16. 2 
22. 2 
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TABLE 29-B 
ERYTHROBLASTOSIS FETALIS: 
TRANSFUSION GIVEN 
Subgroup Cases Within Control: Statistical 
The Subgroup Remaining Cases Significance 
Number 
of Cases 
Percent of 
Cases 
Number 
of Cases 
Percent of 
Cases n t P^ 
I. All Cases 25 
Receiving 
Transfusions 
4o% 
Receiving 
Transfusions 
II. Maternal 0 15 53! 10 20! 23 1.696 0.15 
a. PSP 0, EF 0 10 ho! 15 ho! 23 insignificant 
b. PSP 0, EF A 2 50% 23 39! 23 insignificant 
c. PSP A, EF A 2 50% 23 39! 23 insignificant 
d. PSP 0 or A, k 50% 21 38! 23 0.434 0.70 
EF A 
III. Maternal A 9 33! 16 hh% 23 insignificant 
a. PSP A, EF A 6 33! 19 k2! 23 insignificant 
b. PSP A, EF 0 3 33! 22 hi! 23 insignificant 
IV. PSP or EF ABO Type 
Different From 8 33! IT hi! 23 insignificant 
Maternal ABO Type 
V. Somatic Index ^13 12 25! 13 5k! 23 1.460 0.20 
VI. Cyclopropane 
Anesthesia 11 36! 14 43% 23 insignificant 
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IV. DISCUSSION 
The most striking finding of the preceding data is the 
preponderance of negative correlations. These are summarized 
in Table 30. 
TABLE 30 
NEGATIVE CORRELATIONS, BETWEEN MATERNAL BLOOD 
TYPES, SOMATIC INDEX, AND CYCLOPROPANE 
ANESTHESIA, OCCURRED WITH THE FOLLOWING: 
Maternal: Age, 
Abortion, cervical dilatation and curettage history. 
PSP: Duration of pregnancy. 
Duration of labor, including each of the three stages. 
Spontaneous vs. manual delivery of the placenta. 
Use of oxytocics before and after placental delivery. 
Spontaneous vs. artificial rupture of membranes. 
Duration of nitrous oxide anesthesia. 
Birth canal lacerations at delivery, 
Estimated blood loss at delivery, 
Sex of child. 
EF: Sex and weight of child. 
Normal physical examination. 
Transfusions. 
Noteworthy among these findings is the lack of confirmation of the 
hypothesized association between the development of erythroblastosis 
fetalis and manual removal of the placenta.^ in this series of 25 
cases with controls, there were three manual removals of the placenta, 
all three occurring in the control population (see Table 11-A, page28.). 
For the hypothesis to be true and consistent with these data, one would 
have to further speculate that manual removal of the placenta in the 
presumed senitizing pregnancy be associated with stillborn erythroblastotic 
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infants, that subgroup having been eliminated from this series. 
Another negative finding is that among the subgroup in which 
the maternal type is different from either that of the PSP or EF 
child the prognosis is not significantly different from the ABO 
maternal - PSP-EF compatible group (see Tables 28-B and 29-B, pages 62 
"l 
and 54.) This agrees with the findings of Kelly and Jacobs , but 
differs from the findings of Reepmaker et al§ and Donohue 17. 
Positive data regarding the presence of absence of disease, 
suggesting an association of possible pathogenetic importance, involve 
data in four areas: I. Maternal height, weight, and somatic index from 
the presumed sensitizing pregnancy and delivery; 2. Rectal and vaginal 
examinations; 3. Anesthesia, and| k. Birth weight. 
I. Positive data concerning maternal height, weight and 
somatic index: 
a. PSP or EF, ABO type different from maternal ABO type 
(8cases) - the mother is taller in the EF subgroup than in the control 
(n=lU, P *0.001). 
b. Maternal type A (9 cases) - the somatic index is 
greater in the EF subgroup than in the control (n=l6, PzO.Ol). 
c. Maternal type 0, PSP 0 or A, EF A (h cases) - the 
mother is taller (n=6, P ^0.015) and heavier (n=6, P^ 0.005) in the 
EF subgroup than in the control. 
d. Maternal type A, PSP A, EF 0 (3 cases) - the mother 
is taller (n=4, P^0.03)and the somatic index greater (n=l+, P^O.Ol) 
in the EF subgroup than in the control. 
e. Maternal type 0, PSP 0, EF A (2 cases) - the mother 
is taller in the EF subgroup than in the control (n=2, PzO.oU). 
In evaluating these positive findings, it should be remembered in 
caution that not only are the subgroups small (from 2 to 9 cases) but 
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also that in such a large series of correlations a certain num¬ 
ber of positive results are to be expected by chance. Some 400 
correlations have been made, so that at Pz0.05, 5 percent of 400 
yields 20 positive correlations, or at P^O.Ol, 4 positive correla¬ 
tions, which might be expected by chance alone. (In this study 9 
positive correlations occurred at P^O.Ol or less). 
I know of no correlations in the literature between the occurr¬ 
ence of erythroblastosis fetalis and maternal height, weight, and 
body type data. While the data here presented are significant statis¬ 
tically, the smallness of the series (and perhaps random chance) leads 
this observer to infer that the results may be suggestive medically, 
but that additional similarly closely controlled series would be necess¬ 
ary before further conclusions should be attempted. 
2. Positive data concerning rectal and vaginal examinations 
during the first two stages: 
a. Maternal type 0, PSP 0 or A, EF A £4 cases) - the 
number of rectal examinations is higher in the EF subgroup than in 
the control (n=6, P^O.OOl). 
The importance of "splitting", i.e., analyzing a group in terms of 
its subgroups is here well illustrated, for these highly statistically 
significant subgroup data lead to the following results for larger 
groups of which they are a part: PSP or EF* ABO type different from 
maternal ABO type (8 cases) - the number of rectal examinations is 
higher in the EF group than in the control (n=l4, P^0.04); the 
number of rectal plus vaginal examinations is higher in the EF group 
than in the control (n=l4, P.^0.04). These latter two results at P 0.04 
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are significant statistically only by virtue of the contribution 
of the 4 cases at P/: 0.001, a value which is diluted forty-fold 
% 
in this instance by the 4 other cases in the 8 of the larger group. 
This is a good example of medically insignificant, statistically 
significant data. It is necessary to "split” one's data before one 
can justifiably "lump" -them. 
b. Maternal type A, PSP A, EF 0 (3cases) - the number 
of vaginal examinations is greater in the EF subgroup than in the con¬ 
trol (n=4, P^0.04). 
As with the data of maternal height and weight, I know of no 
reference in the literature to the potential contribution of rectal 
and vaginal examinations during the first two stages to later maternal 
isoimmunization. While the data presented imply a correlation within 
certain subgroups of blood type combinations, the smallness of the 
series limits one to inferring that the data are suggestive, but by 
no means conclusive. The obstetric implications of this possible corre¬ 
lation are obvious. 
3. Positive data concerning anesthesia during delivery: 
a. Maternal type 0 - general anesthesia (l4 cases): 
anesthesia was of shorter duration in the EF subgroup than in the control 
(n=26, P^ 0.005). Cyclopropane anesthesia (7 cases): anesthesia was of 
shorter duration in the EF subgroup than in the control (n=l4, P^O.Ol). 
* The reader is referred to the data on pages 36 through 41 to check 
the validity of this observation. 
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b. Cyclopropane anesthesia, all cases (10 cases) - 
anesthesia was of shorter duration in the EF group than in the con¬ 
trol (n=24, Pz0.05). 
c. Maternal type 0, PSP 0, and EF 0 - general anesthesia 
(10 cases): anesthesia was of shorter duration in the EF subgroup than 
in the control (n=17, PxO.Ol). Cyclopropane anesthesia (5 cases): 
anesthesia was of shorter duration in the EF subgroup than in the 
control (n=8, P^0.005). 
d. Maternal type 0, PSP 0 or A, EF A - general anesthesia 
(3 cases): anesthesia was of shorter duration in the EF subgroup than in 
the control (n=5, P^0.05). 
The author undertook this aspect of the study expecting to find, 
if anything, a correlation between later isoimmunization and prolonged 
duration of anesthesia in the presumed sensitizing pregnancy delivery. 
Instead, the data indicate a "protective" effect of prolonged anesthesia, 
especially in association with maternal type 0. Inquiry into possible 
explanation is being made at the time of this writing.1^ 
4. Positive data concerning birth weight of the presumed 
sensitizing pregnancy child: 
PSP or EF* ABO type different from maternal ABO type 
(8 cases) - birth weight of the presumed sensitizing pregnancy child 
is greater in the EF subgroup than in the control (n=l4, P^0.05). 
Finally, in the group of data relating prognosis to the properties 
and events analyzed, results were negative with one exception. Among 
the children with erythroblastosis fetalis the severity of the disease 
correlates with the "Operative Index", that is, with the extent of obstetric 
operative intervention at delivery of the presumed sensitizing pregnancy, 
(see Table 21-B, page 49; n=19, P^0.02). To follow this finding to its 
logical extension, one would be advised to include Cesarean section among 
the obstetric operative interventions and stillborn fetuses within the 
range of clinical erythroblastosis fetalis, each of these groups having 
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been excluded from the present series. If the data of this small 
series are confirmed, one might expect to find the spectrum of 
operative intervention at delivery of the presumed sensitizing 
pregnancy to correlate with the spectrum of prognosis for the first 
affected child. One would expect the least operative interference, 
i.e., spontaneous delivery, to be associated statistically with the 
best prognosis, i.e., a clinically normal neonate; moderate 
operative interference, e.g., low forceps, to be associated statis¬ 
tically with poorer prognosis, e.g., need for neohatal transfusions; 
and the greatest operative interference. Cesarean section, to be 
associated statistically with the worst prognosis, intrauterine 
death. 
At present the small series of data present are certainly sugges¬ 
tive; the potential obstetric implications evident. 
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V. SUMMARY 
1. A series of twenty-five cases of first affected erythroblas¬ 
tosis fetalis children, with appropriately matched non-diseased con¬ 
trols , is presented in terms of clinical obstetrical data relating 
to (a) maternal personal properties, (b) clinical events and proper¬ 
ties of the presumed sensitizing pregnancy, delivery, and child, and, 
(c) the presence and severity of erythroblastosis fetalis. 
2. Positive correlations are found relating increased frequency 
of erythroblastosis fetalis according to various combinations of mat¬ 
ernal, presumed sensitizing pregnancy child, and erythroblastotic 
child blood types, occurring in relation! to (a) maternal height, 
weight, and somatic index, (b) number of rectal and vaginal examina¬ 
tions at delivery of the presumed sensitizing pregnancy, (c) duration 
of anesthesia at delivery of the presumed sensitizing pregnancy and, 
(d) birth weight of the presumed sensitizing child. 
3. Data are presented relating increased severity of prognosis 
to the extent of operative obstetric intervention at delivery of the 
presumed sensitizing pregnancy. 
4. Suggestions for further study are discussed. 
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